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Abstract
Background: Since 2004, artemisinin-based combination therapy (ACT) has been the first-line treatment for uncomplicated malaria in Benin. In 2016, a medicine outlet survey was implemented to investigate the availability, price, and
market share of anti-malarial treatment and malaria diagnostics. Results provide a timely and important benchmark to
measure future interventions aimed at increasing access to quality malaria case management services.
Methods: Between July 5th to August 6th 2016, a cross sectional, nationally-representative malaria outlet survey was
conducted in Benin. A census of all public and private outlets with potential to distribute malaria testing and/or treatment was implemented among 30 clusters (arrondissements). Outlets were eligible for inclusion in the study if they
met at least one of three study criteria: (1) one or more anti-malarials reportedly in stock on the day of the survey; (2)
one or more anti-malarials reportedly in stock within the 3 months preceding the survey; and/or (3) provided malaria
blood testing. An audit was completed for all anti-malarials, malaria rapid diagnostic tests (RDT) and microscopy.
Results: 7260 outlets with the potential to sell or distribute anti-malarials were included in the census and 2966 were
eligible and interviewed. A total of 17,669 anti-malarial and 494 RDT products were audited. Quality-assured ACT was
available in 95.0% of all screened public health facilities and 59.4% of community health workers (CHW), and availability of malaria blood testing was 94.7 and 68.4% respectively. Sulfadoxine–pyrimethamine (SP) was available in
73.9% of public health facilities and not found among CHWs. Among private-sector outlets stocking at least one antimalarial, non-artemisinin therapies were most commonly available (94.0% of outlets) as compared to quality-assured
ACT (36.1%). 31.3% of the ACTs were marked with a “green leaf” logo, suggesting leakage of a co-paid ACT into Benin’s
unsubsidized ACT market from another country. 78.5% of the anti-malarials distributed were through the private
sector, typically through general retailers (47.6% of all anti-malarial distribution). ACT comprised 44% of the private
anti-malarial market share. Private-sector price of quality-assured ACT ($1.35) was three times more expensive than
SP ($0.42) or chloroquine ($0.41). Non-artemisinin therapies were cited as the most effective treatment for uncomplicated malaria among general retailers and itinerant drug vendors.
Conclusions: The ACTwatch data has shown the importance of the private sector in terms of access to malaria treatment for the majority of the population in Benin. These findings highlight the need for increased engagement with
the private sector to improve malaria case management and an immediate need for a national ACT subsidy.
Keywords: Benin, Malaria case management, Private sector, Public sector, Artemisinin-based combination therapy,
Diagnostic test, ACT subsidy
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Background
In Benin, important gains in malaria control have been
achieved in recent years, however, malaria remains a leading cause of morbidity and mortality. In 2015, the World
Health Organization (WHO) reported over two million
confirmed malaria cases and 1416 deaths in the country [1]. Malaria is cited as the leading reason for medical
consultations and hospitalization in Benin [2]. According
to population based surveys, only 28% of children under 5
received the first-line treatment for uncomplicated malaria
[3] and among pregnant women, only one in four were
found to use intermittent treatment as prevention during
pregnancy (IPTp) [4]. The financial impact of malaria is
also of concern in Benin. It is estimated that households
spend approximately one-quarter of their annual income
on the prevention and treatment of malaria, meanwhile,
37% of the Benin population live below the poverty line,
with a per capita annual income of only $750 [5].
In 2004, the policy for malaria management in Benin
changed when the National Malaria Control Programme
(NMCP) introduced artemisinin-based combination therapy (ACT), artemether–lumefantrine (AL), for treatment
of uncomplicated malaria [1]. Up to that time, chloroquine
had been used for first-line therapy against uncomplicated
malaria. In 2011, the guidelines changed and stipulated that
patients of all ages should receive a confirmatory malaria
test prior to treatment. In 2014, updates to national policy
brought malaria to case management guidelines further inline with WHO recommendations and stipulated three doses
of sulfadoxine–pyrimethamine (SP) for IPTp. The NMCP
also updated the malarial national case management guidelines to align with the WHO recommendation for treatment
of severe malaria with injectable artesunate and injectable
artemether [6], though injectable quinine is also still recommended followed by a seven day treatment with oral quinine.
Treatment for severe malaria should only be administered at
a public or private hospital. Oral artemisinin monotherapies
have been banned in Benin since 2008 [1].
As a means to promote universal coverage of first-line
treatment and increase rates of confirmatory testing, the
NMCP took significant steps to improve malaria case
management services across the country. In 2011, publicsector initiatives included free malaria case management
to children under 5 years of age and pregnant women.
Prior to this, public health facilities had charged fees for
consultation, medications, and procedures [7]. The 2014–
2018 National Malaria Strategic Plan was also developed
and set the goal that by 2030, “…malaria would no longer
be a public health problem in Benin” [6]. The strategy
aims to decrease the number of annual cases by 75% and
reduce the mortality rate to 1 death per 100,000 people.
There has been a substantial increase in the procurement of ACT and malaria rapid diagnostic tests (RDT)
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as a means to increase universal access to malaria commodities. In 2014, over 1.3 million RDT were procured
and in 2015, this increased to almost 1.5 million [1]. A
similar pattern followed for the procurement of ACT,
which increased from 1.1 million in 2014 to 1.2 million
in 2015. Commodities such as ACT and RDT have largely
been made available through the public-sector channels.
Other initiatives to improve malaria case management
services include expanding access to primary health care
services through the training and equipping of community
health workers (CHW), including training on the appropriate use of RDT as well as the management of malaria,
pneumonia, diarrhoea, and malnutrition [6]. In 2014, it was
estimated that over 12,500 CHW were active in the country. Other public-sector initiatives have included funds for
the provision of free healthcare to the extremely poor, and
the reinforcement of health financing schemes [8].
There have been no major initiatives targeting the
private sector in Benin to improve malaria case management services, despite evidence that over 70% of antimalarials are distributed through this channel [9]. While
the national strategy has included the provision of diagnosis, microscopy or RDT, and ACT in selected private
health clinics [10], the scale-up is largely in process and
has yet to be routinely implemented [6]. Indeed, the private sector in Benin is renowned for being diverse and
continuously expanding, with most providers operating
informally without a license, mainly because the accreditation process is often perceived as difficult and conveying few benefits [6, 11]. While there is a push to simplify
the process by bringing more of the private sector into
the formal market, this has yet to be widely implemented.
This lack of private-sector engagement contrasts with
several other countries that have benefitted from ACT
subsidies aimed to increase access to first-line treatment
in the private sector. The most notable of these initiatives
was the Affordable Medicines Facility-malaria (AMFm),
which continued through 2016 [12, 13] and was implemented in neighbouring Nigeria, as well as seven other
countries (Cambodia, Ghana, Kenya, Madagascar, Niger,
Uganda, and Tanzania). Through this mechanism, subsidized ACT was available on the market and labelled
with a ‘green leaf ’ logo to indicate quality-assurance. By
increasing quality-assured ACT on the anti-malarial
market, the AMFm also aimed to decrease the use of oral
artemisinin monotherapies, and non-artemisinin monotherapies, such as chloroquine. Following the AMFm
pilot period, the Global Fund continued to support a
quality-assured ACT subsidy programme through the
Private Sector Co-payment Mechanism (CPM) [14], but
Benin was not part of this initiative.
Investigating the anti-malarial and diagnostic market landscape will provide an important benchmark to
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measure future interventions aimed at increasing access to
quality malaria case management services. However, there
is limited rigorous evidence on the availability and distribution of anti-malarials and malaria diagnostics in Benin.
Since 2008, the multi-country ACTwatch project has been
implemented in Benin to fill contemporary evidence gaps
by collecting malaria case management commodity market data on anti-malarial medicines, malaria diagnostics,
market share, and price in both the private and public sectors [15]. The objective of this paper is to provide practical
evidence to inform strategies and policies in Benin towards
achieving national malaria control goals, by describing the
total market for malaria medicines and diagnostics at the
national level according to the most recent survey round.
Evidence will point to recommendations for improving
coverage of appropriate malaria case management.

Methods
This was the fourth outlet survey implemented in Benin,
with previous surveys conducted in 2009, 2011, and 2014
[16–18]. This study used a cross-sectional, multi-staged
cluster sampling approach and was stratified according to
urban/rural areas. The outlet survey followed the design
implemented in previous survey rounds and across other
ACTwatch countries. The outlet survey was implemented
from July 5th to August 6th 2016.
Sampling approach

According to the ACTwatch methodology, outlets are
included in the survey if they have the ‘potential’ to sell or
distribute anti-malarials. This includes outlets that may
not be expected to stock anti-malarial medicines. For
example, while public health facilities would be expected
to have anti-malarials in stock, the extent to which general retailers or itinerant drug vendors have anti-malarials available may be more debatable. To assess this, the
ACTwatch study approach is to include all outlets that
could ‘potentially stock’ anti-malarials.
Outlets sampled in Benin’s public sector included
public health facilities (including the national referral
hospital, regional hospitals, district hospitals, health
centers and dispensaries); CHW and private not-forprofit facilities (including non-governmental organisations, hospitals and clinics, and faith-based hospitals
and clinics). The private-sector outlet types sampled
were private for-profit health facilities (including private hospitals, clinics and diagnostic laboratories); pharmacies (which are registered and licensed by a national
regulatory authority); drug stores (Depôts pharmaceutiques); general retailers (grocery stores, kiosks and
market stalls selling fast-moving consumer products);
and itinerant drug vendors (mobile, unregistered providers selling medicines).
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The primary sampling approach taken for ACTwatch
outlet surveys entails sampling a set of administrative
units (geographic clusters) with a population of approximately 10,000–15,000 inhabitants. The most appropriate administrative unit in Benin matching the desired
population size was an ‘arrondissement’. A representative
sample of arrondissements was selected using probability proportional to population size sampling, using data
from Benin’s fourth Population and Housing census.
As public health facilities, pharmacies, and drug
shops (dépôts pharmaceutiques) are important providers of anti-malarials but are relatively uncommon, oversampling was conducted for these outlet types in Benin.
This ‘booster’ sample was obtained by including all public health facilities, pharmacies, and drug shops (dépôts
pharmaceutiques) located in the larger administrative
area (called a ‘commune’ in Benin) from which a given
arrondissement was selected. In this instance, the booster
sample covered all public health facilities, pharmacies,
and drug shops in the whole commune within which the
arrondissements were located.
The sample was stratified by urban–rural ward designation. In total, 15 arrondissement were selected for the
main census sample (15 rural, 15 urban). Within each
selected arrondissement a census of all outlet types with
the potential to provide anti-malarials or diagnostics to
consumers was undertaken.
Eligibility criteria

Outlets were eligible for a provider interview and malaria
product audit if they met at least one of three study criteria: (1) one or more anti-malarials reportedly in stock
on the day of the survey; (2) one or more anti-malarials
reportedly in stock within the three months preceding the
survey; and/or (3) provided malaria blood testing (microscopy or RDT). Among eligible outlets, providers were
interviewed and all anti-malarials and RDTs were audited.
Sample size

A series of calculations was completed to identify minimum
sample size requirements to detect an increase or decrease
in the availability of quality-assured ACT and of malaria
blood testing between 2014 and 2016. Calculations examined the sample size required to detect a 20% point change
among all outlets, the public sector, the private sector, public
health facilities, pharmacies, and general retail outlets.
The required sample size for each research domain
(urban and rural areas) was calculated in three steps: (1)
determine the required number of anti-malarial-stocking
outlets, (2) determine the number of outlets to be enumerated to arrive at this number of anti-malarial-stocking
outlets, and (3) determine the number of arrondissement
for the census to arrive at this number of outlets.
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Required number of anti‑malarial stocking outlets

Data collection

The number of anti-malarial-stocking outlets required to
detect a change over time is given by:

The outlet survey census involved systematically looking
for outlets in each arrondissement and using screening
questions to identify outlets for inclusion in the study. Provider interviews and anti-malarial audits were conducted in
all eligible outlets, after informed consent procedures. Up
to three call-back visits were made to outlets in instances
where outlets were closed or providers were not available.
Data were collected using Android phones, except
in pharmacies that had a large number of anti-malarial
products. In these pharmacies, paper questionnaires
were used so that multiple interviewers could audit antimalarial products simultaneously to shorten the time
required to finish the interview. The electronic data
collection program was developed using DroidDB (©
SYWARE, Inc., Cambridge, MA, USA).

n=


2
√
√
deff × Z1−α 2P(1−P) + Z1−β P1 (1−P1 ) + P2 (1−P2 )
(P2 −P1 )2

where n = desired sample size, P1 = the proportion of
anti-malarial-stocking outlets with quality-assured ACT/
malaria blood testing available in stock in 2014, P2 = the
expected proportion of anti-malarial-stocking outlets
with quality-assured ACT/malaria blood testing available in stock in 2016 (20% point increase or decrease),
P = (P1 + P2)/2, Zα = the standard normal deviation
value for an α type I error (two-sided), Z
 1 − β = the standard normal deviation value for a βtype II error, Deff = the
design effect in case of multi-stage arrondissement sample design. Deff figures from the 2014 dataset were used
in sample size calculations.
Required number of outlets

The estimated number of outlets enumerated needed for
the quality-assured ACT availability indicator was determined by the following formula for outlets within urban
and rural domains:

N = n/Pam

where Pam is the proportion of outlets having antimalarial stocks at the time of the survey among all outlets enumerated. In this equation, the assumptions are as
follows: N = desired sample size of all outlets for monitoring availability indicators, n is the number of outlets
with anti-malarial stocks at the time of the survey. P
 am is
the proportion of outlets having anti-malarials in stock at
the time of the survey among outlets enumerated in 2014
within urban and rural areas. The Pam values documented
in the 2014 ACTwatch outlet survey were used for 2016
sample size calculations.
Required number of arrondissements

The average numbers of outlets by outlet type in arrondissements within urban and rural areas screened during the 2014 outlet survey were used to estimate the
number of arrondissements required in 2016 to achieve
the desired sample sizes. Considering sample size
requirements to detect change over time and average
numbers of outlets across each outlet type, the optimal minimum number of localities required to reach
desired numbers of outlets was 30 arrondissements (15
urban, 15 rural) plus a booster sample of public health
facilities, pharmacies, and drug shops at the commune
level.

Measures

Anti-malarial audit information recorded information
on the formulation, package size, brand name, active
ingredients and strength(s), manufacturer, country of
manufacture, reported sale/distribution in the week preceding the survey, retail price, and wholesale price. The
RDT audit information collected similar data. In addition
to the product audit, a series of questions were administered to the senior-most provider regarding malaria case
management knowledge and practices as well as provider
training and qualifications.
Training

Standard ACTwatch tools and training materials were
used. A training of trainers was conducted in June 2016 and
was followed by a pilot test to evaluate the electronic data
collection program. Interviewers, supervisors, and quality
controllers then received a training that included an orientation to the study, questionnaire overview, including a
focus on how to complete the anti-malarial and RDT audits
and how to use the electronic data collection program.
After the training, a field exercise was conducted outside of the selected arrondissements to provide practical experience for the trainees and to evaluate their
performance. Supervisors and quality controllers were
then chosen from the highest performers in the group,
and these candidates then participated in an additional
three-day training before the start of data collection.
Eight teams were formed, each composed of one supervisor, one quality controller, and five or six interviewers.
Representatives from the research agency, Association
Beninoise pour le Marketing Social (ABMS), and the
ACTwatch central team provided additional supervision
and support to the data collection teams in the field for
the entirety of the data collection.
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Data analysis

Data collected with paper questionnaires were double
entered and verified using a Microsoft Access database.
All data cleaning and analysis was completed using Stata
13.1 (©StataCorp, College Station, TX). Sampling weights
were applied to account for variations in the probability of selection and standard error estimation accounted
for clustering at the arrondissement and commune levels. The sampling weights use for the Benin survey are
described in further detail in Additional file 1.
Standard ACTwatch indicators were calculated in line
with previous outlet surveys [9, 15, 19]. Anti-malarials
were classified as ACT, non-artemisinin therapy, and oral
or non-oral artemisinin monotherapy. ACT were further
classified as quality-assured ACT or non-quality assured
ACT by matching product information to lists of WHO
prequalified anti-malarials and Global Fund anti-malarial
procurement lists.
Availability of any anti-malarial was calculated with all
screened outlets as the denominator. In the public sector, the availability of specific types of anti-malarials was
calculated using the denominator of all screened outlets
given that anti-malarials should be available at all public
health facilities and among CHWs. Availability of specific anti-malarial categories in the private sector was
calculated using the total number of private-sector outlets stocking any anti-malarial as the denominator.
Market share was defined as the relative distribution
of anti-malarials to individual consumers in the week
preceding the survey. In order to allow for meaningful
market share comparisons between products, information about anti-malarial distribution was standardized
to the adult equivalent treatment dose (AETD). AETD is
the amount of active ingredient necessary to treat a 60 kg
adult according to WHO treatment guidelines [20]. Volumes distributed were calculated by converting provider
reports on the number of anti-malarials sold in the week
prior to the survey into AETDs. Volumes were therefore
the number of AETDs sold or distributed by a provider in
the seven days prior to the survey. All dosage forms were
considered when measuring volumes to provide a complete assessment of anti-malarial market share. Public
and private-sector booster sample outlets were excluded
from market share calculations to avoid over-estimating
the role of the private sector.
Median private sector price per AETD was calculated
for quality-assured ACT and other non-artemisinin therapies including chloroquine, SP, and quinine. The interquartile range [IQR] was calculated to demonstrate price
dispersion. Anti-malarial price was collected in West
African Communauté Financière Africaine (CFA) and
converted to United States (US) dollars based on official
exchange rates for the six-week data collection period.
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Provider perceptions regarding the most effective firstline treatment was assessed by administering questions
to the senior most provider at all anti-malarial-stocking
outlets. Providers were asked to describe what medicine
they believed was the most effective treatment for treating uncomplicated malaria in a child and in an adult.

Results
A total of 7260 outlets were screened for availability of
anti-malarials and/or malaria blood testing services. Of
screened outlets 2966 met one of the three screening criteria, including 2959 who were stocking anti-malarials
on the day of the survey or within the past three months
or provided malaria testing. A total of 17,669 anti-malarial and 494 RDT products were audited (Additional
file 2).
Public sector availability

Table 1 shows the availability among all screened public
sector outlets. Availability of any anti-malarial was 95.0%
among public health facilities and 59.4% among CHWs.
Nine in ten public health facilities stocked quality-assured
ACT (89.9%) and 54.8% of CHWs. Among public health
facilities, availability of the four different package AL pack
sizes (6, 12, 18 and 24 tablets) suitable for management of
four different weight categories of patients (5–14; 15–24;
25–34 and ≥35 kg) ranged from 48.8 to 65.9% (Additional
file 3). Among CHW, 50.4% had AL for children 5–15 kg
in stock (a package of six tablets) and availability of other
weight/age formulations was less than 5%. SP was available in 73.9% of public health facilities and was not found
among CHWs. Oral quinine was available in 87.7% of
public health facilities and among 2.3% of CHWs.
Availability of malaria blood testing was 94.7% among
public health facilities and 68.4% among CHWs. Malaria
blood testing stocking rates were largely attributed to the
availability of RDT.
The readiness of public-sector outlets for malaria case
management, defined as stocking both quality-assured
ACT and having malaria blood testing, was 89.0% among
public health facilities and 49.7% among CHWs.
Private sector availability

Among all screened private sector outlets, availability of
anti-malarials was as follows: 85.8%, private for-profit
facilities; 94.6%, pharmacies; 27.5%, general retailers; and
67.7%, itinerant drug vendors (Table 2).
Among the outlets stocking at least one anti-malarial in
stock, 36.1% had a quality-assured ACT. This was most
commonly available among pharmacies (90.0%) compared to private for-profit facilities, general retailers,
and itinerant drug vendors (36.4, 35.4 and 34.2%, respectively). 31.3% of ACTs in the private sector were marked
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Table 1 Availability of anti-malarial and malaria blood testing among all public sector outlets screened
Public health facility

CHW

Total public sectora

% (95% CI)

% (95% CI)

% (95% CI)

N = 298

N = 145

N = 536

Quality-assured ACT

89.9 (83.9, 93.8)

54.8 (32.2, 75.7)

59.4 (43.6, 73.4)

Quality ACT with the ‘green leaf’ logo

3.0 (0.9, 9.8)

0.6 (0.1, 4.3)

4.7 (2.0, 10.8)

Sulfadoxine–pyrimethamine

73.9 (63.9, 81.9)

0.0 (–)

20.6 (14.9, 27.7)

Oral quinine

87.7 (82.7, 91.3)

2.3 (0.4, 11.7)

33.2 (25.0, 42.6)

Chloroquine

0.4 (0.1, 1.6)

0.0 (–)

1.3 (0.5, 3.5)

Oral artemisinin monotherapy

0.0 (–)

0.0 (–)

0.0 (–)

Artesunate injection

5.3 (1.6, 16.6)

0.0 (–)

1.3 (0.4, 4.1)

Artemether injection

6.2 (2.1, 16.7)

0.0 (–)

5.5 (2.5, 11.8)

Quinine injection

79.3 (69.5, 86.5)

4.5 (0.8, 22.1)

32.2 (23.9, 41.9)

N = 298

N = 145

N = 536

Microscopy

28.7 (21.4, 37.2)

0.9 (0.1, 5.1)

8.9 (6.0, 13.0)

RDT

94.4 (89.8, 96.9)

68.4 (47.3, 84.0)

68.3 55.8, 78.7)

N = 298

N = 145

N = 536

1.0 (0.2, 3.6)

5.1 (2.3, 11.0)

5.7 (3.1, 10.2)

Availability of:
Any anti-malarial

95.0 (90.3, 97.4)

Availability of:
Any diagnostic test

94.7 (90.1, 97.2)

Readiness for malaria case management:
Quality-assured ACT and malaria testing available
Quality-assured ACT no malaria testing available
a

59.4 (40.2, 76.1)

68.4 (47.3, 84.0)

89.0 (82.7, 93.2)

49.7 (28.4, 71.2)

72.6 (58.1, 83.5)

69.4 (56.9, 79.6)

53.7 (39.2, 67.6)

Includes public non-for profit sector (N = 93)

Table 2 Availability of anti-malarial and malaria blood testing among the private outlets

Among all screened outlets:
Availability of any anti-malarial

Private for-profit facility Pharmacy

General retailer Itinerant drug vendor Total private sectora

% (95% CI)

% (95% CI)

% (95% CI)

% (95% CI)

% (95% CI)

N = 262

N = 176

N = 5622

94.6 (76.5, 99.0) 27.5 (21.9, 34.0)

N = 632

67.7 (38.8, 87.4)

N = 6724

33.3 (30.2, 36.7)

N = 170

N = 1388

N = 468

N = 2278

85.8 (77.6, 91.3)

Among anti-malarial stocking outlets, N = 222
availability of:
Quality-assured ACT

36.4 (23.0, 52.2)

90.0 (75.0, 96.5) 35.4 (27.9, 43.8)

34.2 (22.3, 48.4)

36.1 (27.7, 45.5)

Quality-assured AL

35.9 (22.7, 51.6)

89.5 (74.9, 96.1) 35.1 (27.5, 43.6)

34.2 (22.3, 48.4)

35.9 (27.5, 45.3)

Quality ACT with the ‘green leaf’
logo

25.0 (15.5, 37.6)

0.1 (0.0, 0.8)

33.2 (25.7, 41.7)

28.9 (17.1, 44.6)

31.3 (23.0, 41.0)

12.7 (8.4, 18.9)

Non quality-assured ACT

19.3 (13.3, 27.2)

100.0 (–)

Sulfadoxine–pyrimethamine

24.6 (16.2, 35.5)

56.6 (39.5, 72.3) 29.4 (19.8, 41.4)

13.0 (7.5, 21.6)

14.8 (10.6, 20.3)

68.1 (42.9, 85.8)

36.4 (22.1, 53.7)

Oral quinine

70.5 (64.0, 76.3)

67.6 (46.7, 83.2) 34.3 (21.1, 50.5)

60.1 (36.1, 80.1)

42.5 (26.1, 60.7)

Chloroquine

11.1

0.0 (–)

38.4 (19.0, 62.4)

59.2 (39.9, 76.1)

71.3 (54.7, 83.6)

Other non-artemisinin

3.4 (1.3, 8.4)

15.6 (8.6, 26.6)

2.1 (1.3, 3.4)

8.6 (5.7, 12.8)

3.6 (2.1, 6.0)

Oral artemisinin monotherapy

0.0 (–)

0.0 (–)

0.0 (–)

0.0 (–)

0.0 (–)

Artesunate injection

1.5 (0.5, 4.3)

23.9 (14.5, 36.8) 0.0 (–)

0.0 (–)

0.5 (0.2, 0.9)

Artemether injection

28.8 (19.9, 39.7)

70.3 (55.5, 81.8) 0.8 (0.3, 2.2)

0.0 (–)

4.1 (2.9, 5.8)

Quinine injection

82.7 (75.7, 88.0)

Among outlets stocking anti-malarials N = 233
today or within the past 3 months,
availability of:

30.4 (19.0, 44.9) 1.7 (0.8, 3.7)

0.0 (–)

8.7 (6.4, 11.8)

N = 170

N = 496

N = 2459

N = 1530

Any diagnostic test

39.2 (30.6, 48.5)

5.0 (1.4, 16.0)

0.1 (0.0, 0.3)

0.0 (–)

3.3 (2.3, 4.7)

Malaria microscopy

17.9 (8.7, 33.2)

0.0 (–)

0.0 (–)

0.0 (–)

1.5 (0.8, 2.8)

RDT

26.1 (16.8, 38.3)

5.0 (1.4, 16.0)

0.1 (0.0, 0.3)

0.0 (–)

2.2 (1.3, 3.8)

a

Total private sector includes 32 drug stores
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with the ‘green leaf ’ logo. Adult quality-assured ACT was
available in 24.6% of private-sector outlets. The three
child formulations were available in less than 15% of the
private sector (Additional file 4).
Chloroquine was available in 59.2% of the private sector followed by oral quinine (42.5%) and SP (36.4%),
though there were several differences across outlet types.
For example, chloroquine was most commonly stocked
by general retailers (71.3%) while SP was most commonly
available among itinerant drug vendors (68.1%) and oral
quinine was available in 70.5% private for-profit facilities.
Anti‑malarial market share

Figure 1 shows the market share of different categories
of anti-malarials sold or distributed in the 7 days prior to

Non-oral artemisinin monotherapy

100

Oral artemisinin monotherapy
Other non-artemesinin therapy

90

PERCENTAGE OF TOTAL MARKET VOLUME

the survey. A total of 25,427 anti-malarial AETDs were
reportedly distributed in seven days before the survey.
21.5% of the anti-malarial market share was distributed by the public sector, which was comprised mostly
of quality-assured ACT without the ‘green leaf ’ logo
(9.9% of total market share) and of SP (6.5% of the total
market).
Almost 80% of the anti-malarials distributed were
through the private sector (78.5%). Quality-assured
ACT with the ‘green leaf ’ logo comprised 15.6% of the
total anti-malarial market share, followed by non-quality
assured ACT (without the logo), which comprised 14.3%.
SP made up the largest market share of non-artemisinin
therapies (24.7%), followed by chloroquine (13.3%) and
oral quinine (6.5%).
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Overall, general retailers dominated the anti-malarial
market, accounting for 47.6% of the total market share in
Benin, and these providers distributed most of the quality-assured ACT with the ‘green leaf ’ logo (13.4% of total
market share), SP (14.7%), and chloroquine (12.0%).
Malaria diagnostic market share

Figure 2 shows the diagnostic market share of different
types of malaria tests administered in the seven days
prior to the survey. A total of 6712 malaria test units,
either microscopy or RDT, were reportedly distributed or
used in the seven days prior the outlet survey.
Most of the malaria testing was performed through
the public sector, which accounted for 82.2% of the total
diagnostic testing market share. Microscopy testing was
rare across both the public and the private sector, 14.8
and 6.8% respectively.
Within the private sector, malaria blood testing market
share was dominated entirely by private for-profit health
facilities since none of the other private sector outlets reportedly distributed or sold malaria testing in the
seven days before the survey.
Price

PERCENTE OF TOTAL MARKET VOLUME

Private sector price of AETD quality-assured ACT
($1.35, inter quartile range [IQR] $1.0, $2.02) was
three times more expensive than SP ($0.42, IQR $0.34,
$0.51) or chloroquine ($0.41, IQR $0.41–$0.42). The
price of AETD quinine was $3.54 (IQR $2.83–$4.25)—
2.6 times more expensive than one quality-assured
ACT.

Provider perceptions of most effective treatment

When providers were asked what they perceived to be
the most effective anti-malarial for the treatment of
uncomplicated malaria in children or adults, results
from the public sector illustrate that most providers
cited an ACT. Among public health facility providers,
94.6 and 96.4% perceived ACTs was the most effective
treatment in adults and in children respectively (Figs. 3,
4). Specific to the question regarding the most effective
treatment for adults, 37.2% of CHWs responded that
they did not know, while 59.8% perceived ACT as the
most effective for an adult and 91.8% of them perceived
an ACT as the most effective for children.
In the private sector, 62.7% of private for-profit and 93%
of pharmacy providers cited an ACT as the most effective treatment for adults, and 73.4 and 94.9% respectively
cited this as most effective for children. Non-artemisinin
therapies, typically chloroquine and quinine, were cited
as most effective treatment among general retailers (chloroquine, children: 24.8%; adults: 34.4%; quinine, children:
15.4%; adults: 18.3%) and itinerant drug vendors (chloroquine, children: 17.6%; adults: 29.8%; quinine, children:
43.1%; adults: 30.5%). SP was commonly cited as the
most effective treatment for adults by itinerant drug vendors (29.8%).

Discussion
The 2016 outlet survey provided a complete picture of the
malaria testing and treatment landscape across the public
and private sectors, providing information on availability, market share, price, and provider perceptions. The
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Fig. 3 Providers’ perceptions of the most effective treatment for an uncomplicated malaria in a child

findings point to recommendations for improving private-sector malaria case management in Benin.
Public sector readiness for appropriate malaria case
management

Public health facilities showed high readiness for appropriate case management in Benin. There was nearly universal
coverage of quality-assured ACT treatment and malaria
blood testing in these facilities. These findings reflect
national strategies that have been in place since 2011,
which stipulate confirmatory testing prior to treatment
for all ages and at all levels of care [6]. The current levels
of readiness reflect a substantial increase from diagnostic
availability measured in 2011, where just over half of the
public health facilities had malaria testing available (56.8%)
[17], illustrating that national policy has been successful in
increasing access to confirmatory testing in this sector.
Three-quarters of public health facilities had SP available for IPTp treatment, reflecting an increase over
time, from 17.2% in 2011 and 44.7% in 2014. This suggests substantial progress has been made with regards to
the scale-up of SP for IPTp [17, 18]. This is in-line with
recent national strategies to increase access to SP, including changes to the dosing regimen, and efforts to provide
malaria services free of charge to pregnant women [6].
Availability of oral quinine, recommended for the treatment of uncomplicated malaria in pregnancy during the
first trimester, was also high, with over 85% of public
health facilities stocking this medicine. These findings
illustrate overall readiness among public health facilities
to manage malaria in pregnant women.

According to the 2015 national guidelines, injectable quinine followed by oral quinine are still the recommended treatment for severe malaria, which could
explain the high levels of quinine availability in public
health facilities. However, it is possible that quinine is
being used for uncomplicated malaria given it is widely
available throughout all types of public health facilities. Quinine should only be administered at hospitals,
which would be equipped to manage patients with severe
malaria. Furthermore, while a full course of quinine tablets are indicated for treatment of severe malaria, this
should only be administered after a primary treatment
with injectable quinine. However, market share data illustrate that oral quinine comprises one in every fifth antimalarial distributed in the public sector, while quinine
injection is negligible, suggesting that oral quinine may
be routinely administered for uncomplicated malaria.
Indeed, a recent household study in southern Benin
found quinine was the second most used anti-malarial
for self-medication (after ACT) suggesting that efforts
are needed to ensure the appropriate administration of
this anti-malarial [21]. Despite the updated WHO standards, artesunate availability remains low (5.3%). Efforts
are currently underway to identify the barriers to increasing injectable artesunate use for severe malaria treatment
in Benin [6].
Since 2014, the reach of the public sector has been
extended to the community-level through the training
and equipping of CHWs with malaria case management
skills and supplies (AL and RDT). Since then, several
investments have been made to increase the capacity
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and coordination of these providers [6]. The results from
this survey illustrate how more than half of the CHWs
had anti-malarials in stock, namely quality-assured ACT,
and almost 70% had RDTs. The availability findings also
reflect promising changes from earlier survey rounds
where availability of ACT in 2011 was less than 50% and
the availability of RDT was negligible (<5%). Furthermore, most CHWs perceived ACT to be the most effective treatment for uncomplicated malaria in adults and
children. These findings point to the success of a national
level campaign to scale-up, train, and supply CHWs to
provide ACT and blood testing services. Key areas to
address may be improving CHW awareness of the most
effective anti-malarial for adults given 40% did not know
what this was, and to maintain supply of RDTs as a means
to increase access to confirmatory testing.
Role of the private sector in malaria case management

Results from the study confirmed the dominant role of
the private sector across Benin, where almost 80% of all
anti-malarials passed through this sector, mainly through
general retailers—which accounted for almost half of
the anti-malarial market share in 2016 (47.6%) [17, 18].
Of the 5600 general retail outlets that were screened for
anti-malarials, over one in four had anti-malarials in
stock, reflecting a three-fold increase from previous surveys. General retailers as a source of anti-malarial treatment have also been documented in other countries,
including Madagascar, Myanmar, and Cambodia [22–24],
and were also a common source of treatment in Benin as
evidenced in a population based survey [25]. The results
also point to the importance of itinerant drug vendors,
of which over half of those surveyed had anti-malarials

available, and comprised around one tenth of the antimalarial market share. Trend data also illustrate how the
combined anti-malarial market share of general retailers and itinerant drug vendors, subsequently referred to
as the ‘informal’ private sector, has increased over time
from 30.9% in 2011, 40.1% in 2014, to 56.8% in 2016 [17,
18], illustrating the increasing relevancy of these outlets
in the delivery of anti-malarial treatment. It is unclear
why an increase in the informal market composition has
been observed. Given there is little regulation of the private sector in Benin, this growth of the informal sector
market composition may reflect a natural evolution of the
market to meet consumer demand for anti-malarials, and
perhaps these outlets are more accessible to patients. In
absence of regulation, general retailers and itinerant drug
vendors have perhaps responded to consumer demand by
stocking anti-malarials in addition to other products.
Given a large portion of the private-sector case management is being channeled through these informal outlets, there may be several opportunities to strengthen
the malaria case management services provided by these
vendors. There are examples in the literature of innovative strategies that have focused on general retailers and
itinerant drug vendors to improve access to qualityassured ACT [24]. There is also a growing body of support for itinerant drug vendors as a means to improve
home-based management of malaria [26, 27], and these
mobile providers have been cited as a useful means to
improve the provision of care for malaria [28]. In Benin,
there is also documentation of ‘associations’ of drug vendors, which operate within traditional markets and perform quasi-regulatory functions [11]. The quasi-formal
nature of these vendors may make them suitable for
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accreditation programmes as a means to further regulate, supervise, and engage with the private sector in
both ACT and RDT distribution. Such strategies, done
in collaboration with the public sector, may help to complement rather than compete with the existing CHW
programme. Considering the informal sector in the
accreditation process may be an important strategy to
accelerate coverage of appropriate case management in
Benin.
Readiness of the private sector in malaria case
management

The private sector was generally less well-equipped to test
and appropriately treat malaria infections as compared
with the public sector. Only one-third of private-sector
outlets were stocking quality-assured ACT. Non-artemisinin therapies were more commonly available and distributed. Availability of malaria testing was also negligible
and consistent with these findings, most malaria tests
were administered by the public sector, which comprised
over 80% of the diagnostic market share. Given most private-sector outlets were not stocking malaria tests suggests that presumptive treatment is widespread.
Availability and market share of ACT

While the AMFm or subsequent CPM programme was
not implemented in Benin, most of the quality-assured
ACT reportedly distributed in the private sector had the
AMFm ‘green leaf ’ logo. This indicates leakage of antimalarials’ from other countries and suggests that antimalarials are being illegally traded into non-subsidized
private markets.
The widespread availability and distribution of quality-assured ACT with the logo is perhaps not surprising
considering Benin’s supply chain [11]. The domestic antimalarial market in Benin is relatively small, with few local
manufacturers, so the country’s supply relies heavily on
imports. Many of the anti-malarial supplies are obtained
from more developed pharmaceutical markets in surrounding countries, most notably Nigeria, and imported
largely though the informal sector. Thus, it is quite likely
that products with the ‘green leaf ’ logo—a marker of the
subsidized CPM ACT—have leaked into Benin’s privatesector outlets through neighbouring Nigeria. In fact,
prior to the AMFm, the importation of medicines illegally
from Nigeria was noted as commonplace, with vendors
citing ease of accessing cheap suppliers in Lagos as a key
reason for the illegal import [11]. The widespread uptake
of this illegally imported ACT speaks to the need for a
national level programme targeting the private sector
with subsidized quality-assured ACT to align the privatesector outlets with national treatment guidelines, as well
as a need to strengthen border control and regulation.

Page 12 of 15

Availability and distribution of other non-quality
assured ACT was also high, comprising 14.3% of the antimalarial market and reflecting a slight increase from earlier survey rounds [16, 17]. This is of concern given that
non-quality assured ACT medicines have not received
pre-qualification, meaning that these medicines have
not necessarily been manufactured according to quality standards yielding safe and efficacious medicines.
Moreover, non quality-assured ACT have an increased
likelihood of being poor quality as evidenced by studies
that have tested the pharmacological properties of the
medicines [29]. The widespread presence of non-quality
assured ACT is of concern given its presence on the market and use poses a threat to appropriate and effective
malaria case management.
Availability of different AL formulations

While the strength of all first-line AL tablets for treatment of uncomplicated malaria is indeed the same, the
implementation of the AL policy includes delivery of four
different AL pack sizes (6, 12, 18 and 24 tablets) suitable
for management of four different weight categories of
patients (5–14; 15–24; 25–34 and ≥35 kg). In the private
sector, as well as the public sector, availability of the different weight categories was relatively poor. For example,
in the private sector, only 11.4% of the private for-profit
facilities and 58.6% of pharmacies had AL treatments for
children under 5.
Maintaining a consistent supply of age/weight appropriate commodities will be key to ensure that ACT
commodities are administered according to the recommended age and weight band of each patient and to
prevent medicine packages from being cut or tampered
with. This is particularly important given evidence that
AL treatment is up to six times more likely to be prescribed if the weight specific pack is in stock [30]. While
several strategies are underway to better manage the supply and procurement of malaria commodities to avoid
stock-outs, this has not been fully implemented. Temporary options may be to instruct providers to administer AL even if adequate AL pack sizes are not in stock.
However, evidence suggests that this practice may compromise high levels of patients’ adherence to AL [31] and
incorrect dosing [32, 33]. If adequate availability of firstline ACT treatments cannot be ensured, alternative AL
preparations that do not depend on separate packaging,
could also be considered [30].
Availability and use of non‑artemisinin therapies

Over a decade after the change in first-line treatment
for uncomplicated malaria, non-artemisinin therapies,
including SP, oral quinine, and chloroquine, accounted
for the majority (57.7%) of the market share in the private
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sector. SP made up over half of the non-artemisinin therapies reportedly distributed. While most of the SP distribution was through itinerant drug vendors and general
retailers, SP was also commonly distributed by pharmacies. The widespread distribution of this medicine implies
that it is being used for malaria case management rather
than exclusively for IPTp as recommended. Widespread
availability and distribution of oral quinine, particularly
among general retailers and itinerant drug vendors, also
indicates this is being used for the treatment of uncomplicated malaria.
Widespread distribution of non-artemisinin therapies in Benin might be explained by a number of factors.
This may in part be attributed to price, given that SP and
chloroquine were three times less expensive than qualityassured ACT. Alternatively, access may also be an important factor. Non artemisinin therapies were more widely
available than quality-assured ACT—particularly among
general retailers where most anti-malarials were distributed. Another reason may be around provider perceptions of the most effective treatment for uncomplicated
malaria. In 2016, most of the itinerant drug vendors and
general retailers perceived non-artemisinin therapies (SP,
chloroquine, or quinine) as the most effective treatment
for uncomplicated malaria.
To improve private-sector case management, removal
of non-artemisinin therapies from the market is paramount and new strategies are necessary to curtail their
consumption and promote the use of quality-assured
ACT and RDT in the private sector. Several programmes
have been implemented across sub-Saharan Africa to
improve private sector readiness for appropriate malaria
case management that could be relevant in the Benin
context. A similar nation-wide subsidy to that of the
AMFm may be an immediate means to overcome ACT
access and affordability issues for this treatment, as evidence by the pilot initiative [34, 35]. Once barriers related
to access of quality-assured ACT have been addressed,
mass-media behaviour change campaigns may be a particularly effective strategy in Benin to increase awareness
of the first-line treatment and to promote demand for
the quality ACT product. Several studies have demonstrated how consumer demand is associated with treatment and how patient preferences influence provider
dispensing behaviour [36–39]. Specifically in Benin, qualitative research found that provider stocking decisions
were overwhelmingly driven by patient demand, which
led some outlets not to stock ACT [11]. Furthermore,
provider training and supervision may also be merited
to improve the quality of case management practices,
including accreditation of outlets as previously discussed.
Such multi-pronged strategies are likely to improve
malaria case management and can improve private sector
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readiness and performance, as has been demonstrated in
other contexts [12].
Availability of oral artemisinin monotherapy

Oral artemisinin monotherapy poses a serious threat to
the continued efficacy of artemisinins, and as such this
anti-malarial was banned in Benin in 2008. In 2016, no
oral artemisinin monotherapy was detected in the market. This is of promise given ACTwatch outlet survey
findings from neighboring Nigeria which show that availability of oral artemisinin monotherapy in the private
sector has increased from 24.6% in 2013 to 37.3% in 2015
[40]. Given that Nigeria appears to be a source of supply
of anti-malarials to Benin’s private sector market, it is
important that availability of oral artemisinin monotherapy in the market is routinely monitored. Mystery clients
to detect unwanted or banned medicines may be a useful
method to do this [41].

Limitations
The ACTwatch outlet survey design has limitations that
have been documented and reported [9, 15, 19]. One
point to mention is that while anti-malarial audits were
carried out by researchers, sales volumes were reported
by the provider and these responses were open to positive
response bias. The pros and cons of using self-reported
sales volumes, versus other methods to capture market
share such as sale inventory audits or exit interviewers,
suggests that there are advantages and disadvantages of
different methods but no method is gold standard and
each has its own limitations [42].
Other specific limitations to Benin’s outlet survey
include the use of two different forms of data collection
(electronic and paper questionnaires). While electronic
data collection has the advantage of recording the data
instantly with all the relevant checks and skip patterns
built into the programme, it may have had an impact on
respondents’ fear that they were being recorded or investigated. In addition, some itinerant vendors could have
been missed during the survey given these vendors may
work late at night and, for security reasons, interviewers
only worked during the day and early evening.
Conclusions
The public sector in Benin is typically well equipped to
test and appropriately treat malaria according to national
treatment guidelines. However, the private sector is
responsible for most of the anti-malarial distribution,
typically through general retailers, and this channel most
commonly distributes non-artemisinin therapies. There
is also evidence of leakage of subsidized ACT from neighbouring countries. A national strategy to scale up access
to first-line, quality-assured, subsidized treatment as a
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means to improve coverage and quality of malaria case
management services is needed. Strategies to increase
coverage of malaria commodities should be supported
by interventions to address provider perceptions, as well
as consumer behaviours, and innovative approaches to
either engage or regulate Benin’s informal private sector
are needed.
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